These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21844475)

  • 1. Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment.
    Lerner A; Beckford A; Ugent S; Goldberg L; Jalisi S; Demierre MF
    Arch Dermatol; 2011 Aug; 147(8):998-9. PubMed ID: 21844475
    [No Abstract]   [Full Text] [Related]  

  • 2. Metastatic hidradenocarcinoma: efficacy of capecitabine.
    Jouary T; Kaiafa A; Lipinski P; Vergier B; Lepreux S; Delaunay M; Taïeb A
    Arch Dermatol; 2006 Oct; 142(10):1366-7. PubMed ID: 17043204
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of advanced malignant eccrine poroma with locoregional chemotherapy.
    de Bree E; Volalakis E; Tsetis D; Varthalitis Y; Panagiotidis J; Romanos J; Tsiftsis DD
    Br J Dermatol; 2005 May; 152(5):1051-5. PubMed ID: 15888170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma.
    Obermann H; Schmidle P; Steimle-Grauer SA; Pfarr N; Posch C
    Eur J Cancer; 2021 Mar; 145():143-145. PubMed ID: 33465705
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
    Fürstenberger G; Schmid P; Duquesne A; Ammann M; Senn HJ
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):347-8. PubMed ID: 17896108
    [No Abstract]   [Full Text] [Related]  

  • 6. Capecitabine in the treatment of colorectal cancer.
    Kelly C; Cassidy J
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):803-10. PubMed ID: 17555390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interesting response to concurrent chemoradiation in metastatic eccrine porocarcinoma.
    Yamashita H; Kadono T; Tamaki K; Nakagawa K
    J Dermatol; 2008 Sep; 35(9):606-7. PubMed ID: 18837710
    [No Abstract]   [Full Text] [Related]  

  • 8. Capecitabine.
    Schellens JH
    Oncologist; 2007 Feb; 12(2):152-5. PubMed ID: 17296810
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
    Carstens H; Albertsson M
    Acta Oncol; 2007; 46(6):866-8. PubMed ID: 17653915
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of capecitabine in refractory metastatic medullary thyroid carcinoma.
    Paiva CE; Michelin OC
    Thyroid; 2008 May; 18(5):587. PubMed ID: 18466083
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe hypertriglyceridaemia associated with the use of capecitabine.
    Polinder-Bos HA; Kok EE; van de Wiel A; Spiering W; Wielders JP; Bloemendal HJ
    Neth J Med; 2012 Mar; 70(2):104. PubMed ID: 22418760
    [No Abstract]   [Full Text] [Related]  

  • 12. Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
    Al-Niaimi F; Lyon C
    Clin Exp Dermatol; 2012 Jan; 37(1):68-9. PubMed ID: 21883391
    [No Abstract]   [Full Text] [Related]  

  • 13. Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
    Peramiquel L; Dalmau J; Puig L; Roé E; Fernández-Figueras MT; Alomar A
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S119-20. PubMed ID: 17052530
    [No Abstract]   [Full Text] [Related]  

  • 14. Dramatic response of recalcitrant warts as a side effect of colorectal cancer treatment with oral capecitabine.
    Bel B; Lorton MH; Darut-Jouve A; Vabres P
    Eur J Dermatol; 2011; 21(5):789-90. PubMed ID: 21700544
    [No Abstract]   [Full Text] [Related]  

  • 15. Capecitabine-induced acute myeloid leukaemia.
    Tansley S; Gibbons S
    N Z Med J; 2009 May; 122(1294):118-9. PubMed ID: 19465957
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine.
    Beach DF; Somer R
    J Clin Oncol; 2011 May; 29(14):e397-401. PubMed ID: 21357787
    [No Abstract]   [Full Text] [Related]  

  • 17. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
    Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
    Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
    [No Abstract]   [Full Text] [Related]  

  • 18. Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.
    Koutras AK; Talampuka G; Pagoni N; Thomopoulos KC; Kalliolias G; Kalogeropoulou C; Kalofonos HP
    J BUON; 2007; 12(2):281-3. PubMed ID: 17600885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulomatous septal panniculitis associated with capecitabine (Xeloda).
    Dalmau J; Roé E; Puig L; Alomar A
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):121-2. PubMed ID: 18181993
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine.
    Petekkaya I; Gezgen G; Roach EC; Solak M; Gullu I
    J BUON; 2012; 17(4):796. PubMed ID: 23335544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.